Klin Farmakol Farm. 2025;39(2):111-116 | DOI: 10.36290/far.2025.039

The role of glucocorticoids in rheumatology

Tomáš Lederer, Tomáš Soukup
Subkatedra revmatologie, LF UK a FN Hradec Králové

Glucocorticoids remain an important pillar in the treatment of rheumatologic diseases due to their strong anti-inflammatory and immunosuppressive effects. Their benefit is undeniable, but prolonged use carries significant risks such as accelerated osteoporosis, steroid-induced diabetes mellitus, cardiovascular diseases, and immunosuppression. These risks must be monitored and prevented. By using new approaches, we aim to minimize side effects. Dosage is optimized, and the duration of use is shortened to the necessary minimum. Glucocorticoid therapy is combined with other medications that have a glucocorticoid-sparing effect.

Keywords: glucocorticoids, rheumatology, anti-inflammatory therapy, immunosuppressants, systemic connective tissue disease, arthritis.

Accepted: July 3, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lederer T, Soukup T. The role of glucocorticoids in rheumatology. Klin Farmakol Farm. 2025;39(2):111-116. doi: 10.36290/far.2025.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . Národní zdravotnický informační portál. Kortizol [Internet]. [cited-2025-5-28]. Available from: https://www.nzip.cz/rejstrikovy-pojem/1999.
    2. . Národní zdravotnický informační portál. Adrenokortikotropní hormon [Internet]. [cited-2025-3-28]. Available from: https://www.nzip.cz/rejstrikovy-pojem/2002.
    3. . Národní zdravotnický informační portál. Kortikotropin uvolňující hormon [Internet]. [cited-2025-3-28]. Available from: https://www.nzip.cz/rejstrikovy-pojem/6122.
    4. . Kittnar O, et al. Lékařská fyziologie. Prague: Grada; 2011. p. 506-526.
    5. . Pavelka K, et al. Farmakoterapie revmatických onemocnění. Prague: Maxdorf; 2017. p. 91-98.
    6. . Kopřiva F. Posttranskripční a negenomové účinky glukokortikoidů. Remedia. 2010;20.
    7. . Pavelka K, et al. Revmatologie. 2nd ed. Prague: Maxdorf; 2018. p. 217-223.
    8. . Hayes KN, Baschant U, Hauser B, Burden AM, Winter EM. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Front Endocrinol. 2021;12:782118. Go to original source... Go to PubMed...
    9. . Nelson HS, Leung DYM, et al. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111(1):3-22. Go to original source... Go to PubMed...
    10. . Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am. 2016;42(1):157-176. Go to original source... Go to PubMed...
    11. . Suchý D, Sabitova E. Lékové interakce v revmatologii. Remedia. 2021;31:103-108.
    12. . Rhen T, Cidlowski JA. Antiinflammatory Action of Glucocorticoids - New Mechanisms for Old Drugs. N Engl J Med. 2005;353(16):1711-1723. Go to original source... Go to PubMed...
    13. . Šidáková J, Soukup T, Veleta T. Vybrané urgentní stavy u systémových onemocnění pojiva a systémových vaskulitid. Urgent Med. 2023;26(1):7-16.
    14. . Bělobrádková M, Tomš J, Bělobrádek Z, Soukup T. Poly­myalgia rheumatica a obrovskobuněčná arteritida. Prakt Lék. 2015;11(5):160-163.
    15. . Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560-1567. Go to original source... Go to PubMed...
    16. . Vencovský J. Idiopatické zánětlivé myopatie - některé novější aspekty. Neurol Prax. 2020;21(6):477-484. Go to original source...
    17. . Bečvář R, Soukup T, Štork J, et al. Doporučení České revmatologické společnosti pro diagnostiku systémové sklerodermie. Čes Revmatol. 2014;22(2):51-68.
    18. . Ciferská H, Vachek J. Systémový lupus erythematodes: Nové doporučení pro terapii EULAR 2023. Profi Med [Internet]. 2024 Jun 17 [cited-2025-3-28]. Available from: https://profimedicina.cz/systemovy-lupus-erythematodes-nove-doporuceni-pro-terapii-eular-2023/.
    19. . Ručka D. Aortitis - zánět aortální stěny. Kardio Rev Int Med [Internet]. 2010;12(4):166-170. Soukup T, et al. Systémová sklerodermie. Prague: Maxdorf; 2024. p. 125-131.
    20. . Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69:1521-1537. Go to original source... Go to PubMed...
    21. . Šembera Š, Cyrany J, Tachecí I. Kdy nasazovat inhibitory protonové pumpy. Vnitř Lék. 2024;70(3):158-165. Go to original source...
    22. . Kardaş RC, Küçük H. Perioperative management of patients receiving glucocorticoids in rheumatology. Acta Med. 2024;55(Suppl 1):54-58. Go to original source...
    23. . Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis Rheumatol. 2022;74(4):e21-e36. Go to original source... Go to PubMed...
    24. . Centers for Disease Control and Prevention. COVID-19 Vaccination Considerations for People Who Are Immunocompromised [Internet]. 2025 [cited-2025-3-28]. Available from: https://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.